Clinical Trials Search
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
The purpose of this study is to compare the effects, both good and bad, of magrolimab in combination with azacitidine, to those of azacitidine in combination with placebo, to find out which is better for treating patients with MDS.
The aim of this study is to evaluate the efficacy and safety of magrolimab + azacitidine compared to azacitidine + placebo in previously untreated patients with intermediate/high/very high risk MDS by IPSS-R prognostic risk categories.
Magrolimab/Placebo (); azacitidine (5-azacitidine)
> 18 years of age or older
> Prior treatment with CD47 or SIRPα-targeting agents.